1. Home
  2. BASE vs MESO Comparison

BASE vs MESO Comparison

Compare BASE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BASE
  • MESO
  • Stock Information
  • Founded
  • BASE 2011
  • MESO 2004
  • Country
  • BASE United States
  • MESO Australia
  • Employees
  • BASE N/A
  • MESO N/A
  • Industry
  • BASE EDP Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BASE Technology
  • MESO Health Care
  • Exchange
  • BASE Nasdaq
  • MESO Nasdaq
  • Market Cap
  • BASE 1.3B
  • MESO 1.3B
  • IPO Year
  • BASE 2021
  • MESO N/A
  • Fundamental
  • Price
  • BASE $24.31
  • MESO $15.73
  • Analyst Decision
  • BASE Hold
  • MESO Buy
  • Analyst Count
  • BASE 16
  • MESO 4
  • Target Price
  • BASE $22.97
  • MESO $18.00
  • AVG Volume (30 Days)
  • BASE 713.7K
  • MESO 332.3K
  • Earning Date
  • BASE 09-03-2025
  • MESO 08-28-2025
  • Dividend Yield
  • BASE N/A
  • MESO N/A
  • EPS Growth
  • BASE N/A
  • MESO N/A
  • EPS
  • BASE N/A
  • MESO N/A
  • Revenue
  • BASE $214,662,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • BASE $12.41
  • MESO $178.09
  • Revenue Next Year
  • BASE $13.95
  • MESO $305.06
  • P/E Ratio
  • BASE N/A
  • MESO N/A
  • Revenue Growth
  • BASE 12.76
  • MESO N/A
  • 52 Week Low
  • BASE $12.78
  • MESO $5.78
  • 52 Week High
  • BASE $25.16
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • BASE 70.43
  • MESO 67.42
  • Support Level
  • BASE $24.20
  • MESO $14.45
  • Resistance Level
  • BASE $24.32
  • MESO $17.63
  • Average True Range (ATR)
  • BASE 0.11
  • MESO 0.54
  • MACD
  • BASE -0.21
  • MESO 0.43
  • Stochastic Oscillator
  • BASE 53.33
  • MESO 75.51

About BASE Couchbase Inc.

Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: